<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27625" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Recurrent Pregnancy Loss</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pillarisetty</surname>
            <given-names>Leela Sharath</given-names>
          </name>
          <aff>Midland Memorial / Texas Tech University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahdy</surname>
            <given-names>Heba</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Leela Sharath Pillarisetty declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Heba Mahdy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27625.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The definition of recurrent pregnancy loss (RPL) in the United States is two or more consecutive failed clinical pregnancies documented by ultrasound or histopathology, while, in the United Kingdom, the definition is as having three or more consecutive early pregnancy losses. Up to 50 percent of cases of recurrent pregnancy loss lack a clear etiology. Recurrent pregnancy loss can categorize into primary and secondary types. Primary, recurrent pregnancy loss occurs in women who have never given birth to a live infant. Secondary recurrent pregnancy loss occurs in women who have given birth to a live infant. This activity describes the evaluation, diagnosis, and management of recurrent pregnancy loss and stresses the role of team-based interprofessional care for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the types of recurrent pregnancy loss.</p></list-item><list-item><p>Describe the etiology of recurrent pregnancy loss.</p></list-item><list-item><p>Explain the investigations performed for recurrent pregnancy loss.</p></list-item><list-item><p>Outline the importance of improving coordination among the interprofessional team to enhance care for patients and their families affected by recurrent pregnancy loss.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27625&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27625">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27625.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Recurrent pregnancy loss (RPL) is defined in the United States as two or more consecutive failed clinical pregnancies documented by ultrasound or histopathology.<xref ref-type="bibr" rid="article-27625.r1">[1]</xref> In the United Kingdom, it is defined as having three or more consecutive early pregnancy losses.</p>
        <p>Only about&#x000a0;2 percent of pregnant women have&#x000a0;two consecutive pregnancy losses.<xref ref-type="bibr" rid="article-27625.r2">[2]</xref> Up to 50 percent of patients with RPL have no clearly defined etiology.<xref ref-type="bibr" rid="article-27625.r3">[3]</xref> RPL is one of the complex and challenging scenarios in reproductive medicine, and it is frustrating for the patients, their families, and treating physicians. When the etiology of RPL is unclear, it can create anxiety and apprehension among the patients.</p>
        <p>RPL can be categorized into primary and secondary; primary RPL refers to pregnancy loss in women who never had a live birth. In contrast, secondary RPL is defined as pregnancy loss in women who had a previous live birth.<xref ref-type="bibr" rid="article-27625.r4">[4]</xref></p>
      </sec>
      <sec id="article-27625.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The&#x000a0;etiology of recurrent pregnancy loss (RPL) is broadly&#x000a0;classified into the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Genetic</p>
          </list-item>
          <list-item>
            <p>Anatomic</p>
          </list-item>
          <list-item>
            <p>Endocrine</p>
          </list-item>
          <list-item>
            <p>Antiphospholipid antibody syndrome</p>
          </list-item>
          <list-item>
            <p>Immunological</p>
          </list-item>
          <list-item>
            <p>Environmental factors</p>
          </list-item>
        </list>
        <p><bold>Genetic:&#x000a0;</bold>Aneuploidy is one&#x000a0;of the most common causes of RPL. Balanced, reciprocal, and Robertsonian translocations in the fetus can predispose to spontaneous miscarriages.</p>
        <p><bold><bold>Anatomic:</bold>&#x000a0;</bold>Congenital Mullerian tract anomalies can&#x000a0;cause&#x000a0;RPL. Some of the uterine abnormalities which can predispose to RPL are septate, unicornuate, bicornuate, didelphic, and arcuate uteri. Septate uterus is considered to be the most common congenital uterine anomaly.&#x000a0;A meta-analysis of several studies&#x000a0;concluded that congenital uterine defects were present in about 12.6 percent of the patients with recurrent pregnancy loss.<xref ref-type="bibr" rid="article-27625.r5">[5]</xref>&#x000a0;Acquired&#x000a0;uterine anomalies like fibroids, polyps, and Asherman syndrome can also increase the women's risk for RPL.</p>
        <p><bold>Endocrine:</bold>&#x000a0;Maternal endocrine disorders like diabetes and thyroid dysfunction can cause RPL and must be evaluated and appropriately treated in patients with RPL. Hyperprolactinemia&#x000a0;may be&#x000a0;associated with RPL but is not proven.</p>
        <p><bold><bold>Antiphospholipid antibody syndrome (APLS):</bold>&#x000a0;</bold>accounts for about 8 to 42 percent of patients with RPL. APLS causes an increased risk of thrombosis and placental insufficiency, causing RPL.<xref ref-type="bibr" rid="article-27625.r6">[6]</xref></p>
        <p><bold>Environmental factors:&#x000a0;</bold>Cigarette smoking is suggested to affect trophoblastic function and is linked to an increased risk of RPL. Obesity is independently associated with an increased risk of recurrent pregnancy loss in women who conceive naturally. Other lifestyle habits such as alcohol consumption (3 to 5 drinks per week), cocaine use, and increased caffeine consumption (more than 3 cups of coffee per day) are also associated with an increased risk of spontaneous miscarriages.</p>
        <p><bold>Immunological:&#x000a0;</bold>Routine testing of women with RPL for inherited thrombophilias is not currently recommended.<xref ref-type="bibr" rid="article-27625.r7">[7]</xref>&#x000a0;Screening for inherited thrombophilias may be indicated when a patient has a personal history of venous thromboembolism in the setting of a nonrecurrent risk factor (such as surgery) or a &#x000a0;relative with a known or suspected high-risk thrombophilia. Prospective cohort studies have failed to confirm the association between hereditary thrombophilia and fetal loss.</p>
      </sec>
      <sec id="article-27625.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Only about&#x000a0;2 percent of pregnant women have&#x000a0;two or more consecutive pregnancy losses.<xref ref-type="bibr" rid="article-27625.r2">[2]</xref>&#x000a0;Up to 50 percent of patients with&#x000a0;RPL have no clearly defined etiology.<xref ref-type="bibr" rid="article-27625.r3">[3]</xref></p>
      </sec>
      <sec id="article-27625.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>RPL is a multifactorial condition that may be due to genetic, anatomic, endocrine, antiphospholipid antibody syndrome, immunologic, and environmental factors.</p>
        <p>FOXD1 mutations play a central role in RPL.&#x000a0;FOXD1 was defined as a major molecule involved in embryo implantation in mice and humans by regulating endometrial and placental genes. FOXD1 mutations in human species have been functionally linked to RPL's origin.<xref ref-type="bibr" rid="article-27625.r8">[8]</xref></p>
      </sec>
      <sec id="article-27625.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A thorough and detailed history should be taken and must include all the details of previous pregnancy losses. The gestational age of prior pregnancy loss is critical to know, as RPL typically occurs at a similar gestational age in successive pregnancies. The method of treatment of previous pregnancy loss is also important to know, as dilation and curettage can increase the risk of Asherman syndrome, cervical incompetence, which can&#x000a0;predispose to RPL.</p>
        <p>It is also essential to document full medical (thyroid problems, diabetes), surgical, and menstrual history. Family and personal history of venous and arterial thrombosis, history of smoking, alcohol, drugs, and exposure to environmental toxins must be documented. Physical examination should include a detailed general exam and pelvic exam.</p>
      </sec>
      <sec id="article-27625.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation of couples with RPL should be thorough and should include the following:</p>
        <p>
<bold>Assessment of Medical Problems</bold>
</p>
        <p>Studies should be performed to rule out diabetes, thyroid problems&#x000a0;<xref ref-type="bibr" rid="article-27625.r9">[9]</xref>, and hyperprolactinemia.&#x000a0;</p>
        <p>
<bold>Genetic Evaluation</bold>
</p>
        <p>Karyotype assessment of the couples has to be offered to recognize underlying balanced, reciprocal, or Robertsonian translocations or mosaicism that might be transmitted to the fetus, causing RPL. Though these tests are of low yield and expensive, one should consider evaluating the karyotypes of the couples with RPL.<xref ref-type="bibr" rid="article-27625.r10">[10]</xref><xref ref-type="bibr" rid="article-27625.r11">[11]</xref></p>
        <p>
<bold>Assessment of the Uterine Anomalies</bold>
</p>
        <p>There are several modalities that can be used to identify congenitally and acquired uterine anomalies, some of the valuable tools are the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pelvic ultrasound</p>
          </list-item>
          <list-item>
            <p>Saline infusion sonohysterography</p>
          </list-item>
          <list-item>
            <p>Hysterosalpingogram</p>
          </list-item>
          <list-item>
            <p>Hysteroscopy</p>
          </list-item>
          <list-item>
            <p>MRI is very valuable in identifying congenital uterine anomalies.<xref ref-type="bibr" rid="article-27625.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Immunologic Work Up</bold>
</p>
        <p>Investigations for antiphospholipid antibody syndrome must be undertaken. Measurement of anticardiolipin antibody, lupus anticoagulant, and anti-beta 2 glycoprotein should be done for patients with RPL. Studies have reported that anticardiolipin antibody and lupus anticoagulant has been associated with pregnancy loss, and testing for APAS&#x000a0; for patients with RPL is recommended.<xref ref-type="bibr" rid="article-27625.r13">[13]</xref></p>
        <p>
<bold>Progesterone Level</bold>
</p>
        <p>Routine assessment of&#x000a0;serum progesterone levels is not recommended, as it is not predictive of future pregnancy outcomes.</p>
        <p>
<bold>Endometrial Biopsy</bold>
</p>
        <p>A large number of studies show that this test is not reflective of fertility status in a woman.</p>
        <p>
<bold>Testing for Infections</bold>
</p>
        <p>In a healthy woman without symptoms, routine vaginal and cervical cultures for chlamydia, gonorrhea, bacterial vaginosis, and testing for TORCH serology are not useful in the evaluation of RPL.&#x000a0;</p>
        <p>
<bold>Evaluation of products of Conception (POC)</bold>
</p>
        <p>Using a 24-chromosome microarray analysis adds significantly to the ASRM (American Society of Reproductive Medicine) recommended RPL assessment. Genetic evaluation of miscarriage tissue obtained at the time of the second and subsequent pregnancy losses should be offered to all couples with two or more consecutive pregnancy losses. The combination of a genetic evaluation on miscarriage tissue with an evidence-based assessment for RPL will identify a probable or definitive cause in over 90 percent of miscarriages.<xref ref-type="bibr" rid="article-27625.r14">[14]</xref></p>
      </sec>
      <sec id="article-27625.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment of RPL should be directed towards the underlying treatable cause. Patients and their families should be informed about the risks, alternatives, and success rates of each available treatment option. Treatment success can be increased by providing emotional support for these anxious couples. There should be collaborative teamwork and clear communication between reproductive endocrinologists and obstetricians whenever possible.</p>
        <p>
<bold>Medical Conditions</bold>
</p>
        <p>Women with thyroid conditions, diabetes, obesity, and other medical problems should be treated as medically appropriate. Consultation with an endocrinologist is also a suitable option for the management of uncontrolled thyroid conditions and diabetes. Patients with elevated thyroid peroxidase antibodies are at high risk for RPL and should be managed appropriately.<xref ref-type="bibr" rid="article-27625.r15">[15]</xref></p>
        <p><bold>Chromosomal Anomalies&#x000a0;&#x000a0;</bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>In couples with chromosomal abnormalities, the first step is a referral to genetic counseling. Couples should be educated on the potential likelihood of having fetal chromosomal abnormalities in future pregnancies. They may choose to proceed with</p>
        <p>prenatal genetic testing, such as preimplantation genetic diagnosis,&#x000a0;chorionic villus sampling, or amniocentesis to identify genetic anomalies in the fetus and decide about further treatment options.<xref ref-type="bibr" rid="article-27625.r16">[16]</xref>&#x000a0;Although embryos with unbalanced chromosomal arrangements can theoretically be screened out, PGT (preimplantation genetic testing) is not routinely advised since the likelihood of a pregnancy with an unbalanced karyotype surviving into the second trimester is low.<xref ref-type="bibr" rid="article-27625.r17">[17]</xref></p>
        <p>
<bold>Uterine Anomalies</bold>
</p>
        <p>Congenital and acquired uterine abnormalities causing RPL could be managed surgically. Some of the surgical procedures are hysteroscopic septum resection, lysis of adhesions, myomectomy, and repair of a bicornuate uterus. Referral to a reproductive endocrinologist is appropriate for these surgical interventions whenever possible.<xref ref-type="bibr" rid="article-27625.r18">[18]</xref></p>
        <p>
<bold>Immunological&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; </bold>
</p>
        <p>Patients with antiphospholipid antibody syndrome and RPL are generally treated with aspirin and heparin, and it appears to improve pregnancy outcomes. However, in women with thrombophilias,&#x000a0;this treatment may improve maternal outcomes but does not prevent RPL.&#x000a0;Treatment strategies like aspirin and low molecular weight heparin (LMWH) are standard medications in RPL, although only a few placebo-controlled trials have proven their benefit with respect to live birth rate. There is emerging evidence that new treatment options, including drugs like TNF (tumor necrosis factor-alpha) inhibitors and granulocyte colony-stimulating factor (G-CSF), might be beneficial in some cases of RPL. However, more extensive clinical trials must be completed to further prove or disprove the benefits of these drugs in the treatment of patients with RPL.<xref ref-type="bibr" rid="article-27625.r19">[19]</xref>&#x000a0;Lipid emulsion infusions have been evaluated in only one RCT that tested whether a 250&#x000a0;mL infusion on the day of oocyte retrieval (with further infusions if there was a positive pregnancy test) could increase chemical pregnancy rates in patients with RPL with elevated peripheral blood NK cells (more than 12 percent) undergoing IVF.<xref ref-type="bibr" rid="article-27625.r20">[20]</xref>&#x000a0;The study concluded that&#x000a0;Intralipid supplementation did not increase the frequency of chemical pregnancy. However, findings related to ongoing pregnancy and live birth should be investigated further.<xref ref-type="bibr" rid="article-27625.r20">[20]</xref></p>
        <p>
<bold>Unexplained RPL</bold>
</p>
        <p>A recent meta-analysis using strict criteria for defining unexplained RM found no RCTs involving prednisolone. Two recent meta-analyses of intravenous immunoglobulin (IVIG) use in patients with RPL found no evidence of improved live birth rates.<xref ref-type="bibr" rid="article-27625.r21">[21]</xref></p>
      </sec>
      <sec id="article-27625.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
<bold>Common</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fetal chromosomal abnormality</p>
          </list-item>
          <list-item>
            <p>Idiopathic recurrent miscarriage</p>
          </list-item>
        </list>
        <p>
<bold>Uncommon</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Antiphospholipid syndrome</p>
          </list-item>
          <list-item>
            <p>Cervical incompetence</p>
          </list-item>
          <list-item>
            <p>Parental chromosomal abnormality</p>
          </list-item>
          <list-item>
            <p>Uncontrolled diabetes</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27625.s10" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>The Progesterone in Recurrent Miscarriage (PROMISE) trial involved 836 women with idiopathic recurrent miscarriage randomized to receive either 400&#x000a0;mg of vaginal micronized progesterone twice daily or placebo from the time of positive pregnancy test to 12&#x000a0;weeks gestation.<xref ref-type="bibr" rid="article-27625.r22">[22]</xref>&#x000a0;There was no difference between the two groups in miscarriage or live birth rates. In contrast, another RCT involving 700 women also tested whether the same dose of vaginally administered natural progesterone would benefit unexplained RPL, but unlike the PROMISE trial, that trial commenced treatment in the luteal phase immediately after documentation of ovulation using either ultrasound or luteinizing hormone (LH) kits and continued until 28&#x000a0;weeks gestation. This Egyptian trial found significantly lower miscarriage rates (12.4 versus 23.3 percent) and higher live birth rates (92 versus 77 percent) in the treated group.<xref ref-type="bibr" rid="article-27625.r23">[23]</xref></p>
      </sec>
      <sec id="article-27625.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Recurrent pregnancy loss (RPL) carries a tremendous negative emotional and psychological negative impact on couples. It is associated with&#x000a0;depression, anxiety, and low self-esteem. Increasing maternal age, as well as the number of previous miscarriages, appear to be the most influential independent risk factors for having further pregnancy losses.</p>
      </sec>
      <sec id="article-27625.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Women who experience recurrent pregnancy loss can struggle emotionally and mentally as this diagnosis carries an adverse impact on the women and their families. The couple can suffer due to the psychological impact of repeated pregnancy loss and the feeling that the problem might never end. RPL carries a great deal of frustration, and the couples are continuously aspiring to achieve a successful pregnancy and simultaneously afraid of miscarrying again. RPL carries a negative impact not only on women and their families but also on treating clinicians. It could leave couples with negative emotions like anger, sadness, frustration, and confusion. It could also affect relationships and results in a loss of intimacy.</p>
      </sec>
      <sec id="article-27625.s13" sec-type="Consultations">
        <title>Consultations</title>
        <list list-type="bullet">
          <list-item>
            <p>OB/GYN with a special interest in recurrent pregnancy loss</p>
          </list-item>
          <list-item>
            <p>IVF (in-vitro fertilization) specialists</p>
          </list-item>
          <list-item>
            <p>Infertility specialized nurse</p>
          </list-item>
          <list-item>
            <p>Geneticist</p>
          </list-item>
          <list-item>
            <p>Mental health specialist</p>
          </list-item>
          <list-item>
            <p>Psychotherapist</p>
          </list-item>
          <list-item>
            <p>Bereavement counselor</p>
          </list-item>
          <list-item>
            <p>Hematologist</p>
          </list-item>
          <list-item>
            <p>Immunologist</p>
          </list-item>
          <list-item>
            <p>Endocrinologist</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27625.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is key to the successful management of couples with recurrent pregnancy loss. Healthcare providers play a crucial role in managing couples with RPL. Approaching couples with RPL in a sensitive manner and appreciating their needs, concerns, and their preferences,&#x000a0;taking into account their cultural differences, religious obligations, and wishes is core to the optimal management of this severe diagnosis.&#x000a0;The best possible outcomes for couples with RPL can not be achieved without the active role of every member in the interprofessional team, with regards to helping their patients and their families make informed decisions about their care.</p>
      </sec>
      <sec id="article-27625.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Recurrent pregnancy loss represents a complex challenge in reproductive medicine and causes frustration for the patients, their families, and the healthcare team. Healthcare practitioners should thoroughly counsel patients with recurrent pregnancy loss so that they can make informed decisions about whether they want to go through extensive investigations and treatment. Interprofessional collaboration between endocrinologists, obstetricians, nurses, midwives, and geneticists plays a crucial role in helping couples with recurrent pregnancy loss throughout their journey.</p>
        <p>The nurse should assist the clinician during the investigations and management of couples with recurrent pregnancy loss. The nurse should educate the woman and her family regarding the possible etiologies of their condition and explain the required investigations. The counseling of women with recurrent pregnancy loss requires sensitivity, and the negative emotional burden of their disease merits careful consideration at all times. The provides should provide women with written information leaflets on recurrent pregnancy loss to help them better understand their disease and make informed decisions about their care. Ideally, women should be counseled preconceptionally about the possible underlying modifiable risk factors, such as alcohol, smoking, and caffeine consumption. Women should be advised about taking folic acid&#x000a0;in preparation for pregnancy. RPL carries a tremendous negative impact on women and their families. Therefore, women could benefit from regular follow-up visits with their clinician, interprofessional meetings, and psychotherapy, should it deemed necessary. The providers should inform the couple that there is no specific recommendation that could guarantee the outcome in future pregnancies. Couples with recurrent pregnancy loss need to understand that they have a high chance of having a live birth without any treatments, even after frequent pregnancy&#x000a0;losses. The nurse should assist the clinician in screening couples with RPL for depression and anxiety and should refer couples immediately to mental health specialists, should it deemed necessary. The nurse should inform the clinician about any concerns the couple might have throughout their treatment journey.</p>
        <p>The members of the interprofessional team should ensure that couples with RPL have access to the available community resources. The nurse should provide appropriate referrals to couples with RPL to the patient support groups that could help them cope with the negative emotional burden of their condition. The best possible outcome for couples with recurrent pregnancy loss is not achievable without the harmonious collaboration between the members of the interprofessional team with the core principle of patient-centered care.</p>
      </sec>
      <sec id="article-27625.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27625&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27625">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/womens-health/recurrent-pregnancy-loss/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27625">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27625/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27625">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27625.s17">
        <title>References</title>
        <ref id="article-27625.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <collab>Practice Committee of the American Society for Reproductive Medicine</collab>
            <article-title>Definitions of infertility and recurrent pregnancy loss: a committee opinion.</article-title>
            <source>Fertil Steril</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>99</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <pub-id pub-id-type="pmid">23095139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salat-Baroux</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Recurrent spontaneous abortions].</article-title>
            <source>Reprod Nutr Dev (1980)</source>
            <year>1988</year>
            <volume>28</volume>
            <issue>6B</issue>
            <fpage>1555</fpage>
            <page-range>1555-68</page-range>
            <pub-id pub-id-type="pmid">3073445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stephenson</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Frequency of factors associated with habitual abortion in 197 couples.</article-title>
            <source>Fertil Steril</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>66</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-9</page-range>
            <pub-id pub-id-type="pmid">8752606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ansari</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Recurrent pregnancy loss. An update.</article-title>
            <source>J Reprod Med</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>806</fpage>
            <page-range>806-14</page-range>
            <pub-id pub-id-type="pmid">9777621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grimbizis</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Camus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tarlatzis</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Bontis</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Devroey</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical implications of uterine malformations and hysteroscopic treatment results.</article-title>
            <source>Hum Reprod Update</source>
            <year>2001</year>
            <season>Mar-Apr</season>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-74</page-range>
            <pub-id pub-id-type="pmid">11284660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yetman</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Kutteh</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies.</article-title>
            <source>Fertil Steril</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>66</volume>
            <issue>4</issue>
            <fpage>540</fpage>
            <page-range>540-6</page-range>
            <pub-id pub-id-type="pmid">8816614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <collab>Committee on Practice Bulletins&#x02014;Obstetrics, American College of Obstetricians and Gynecologists</collab>
            <article-title>Practice Bulletin No. 132: Antiphospholipid syndrome.</article-title>
            <source>Obstet Gynecol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>120</volume>
            <issue>6</issue>
            <fpage>1514</fpage>
            <page-range>1514-21</page-range>
            <pub-id pub-id-type="pmid">23168789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bari&#x00161;i&#x00107;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pereza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hod&#x0017e;i&#x00107;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krpina</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ostoji&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peterlin</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Genetic variation in the maternal vitamin D receptor FokI gene as a risk factor for recurrent pregnancy loss.</article-title>
            <source>J Matern Fetal Neonatal Med</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>14</issue>
            <fpage>2221</fpage>
            <page-range>2221-2226</page-range>
            <pub-id pub-id-type="pmid">31446814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Negro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gismondi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tinelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mangieri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stagnaro-Green</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>95</volume>
            <issue>9</issue>
            <fpage>E44</fpage>
            <page-range>E44-8</page-range>
            <pub-id pub-id-type="pmid">20534758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Daya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coulam</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Gunby</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Implication of abnormal human trophoblast karyotype for the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion. The Recurrent Miscarriage Immunotherapy Trialists Group.</article-title>
            <source>Am J Reprod Immunol</source>
            <year>1996</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>495</fpage>
            <page-range>495-8</page-range>
            <pub-id pub-id-type="pmid">8738721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists</collab>
            <article-title>ACOG practice bulletin. Management of recurrent pregnancy loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists.</article-title>
            <source>Int J Gynaecol Obstet</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-90</page-range>
            <pub-id pub-id-type="pmid">12360906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pellerito</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Glickman</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>DeCherney</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of uterine anomalies: relative accuracy of MR imaging, endovaginal sonography, and hysterosalpingography.</article-title>
            <source>Radiology</source>
            <year>1992</year>
            <month>Jun</month>
            <volume>183</volume>
            <issue>3</issue>
            <fpage>795</fpage>
            <page-range>795-800</page-range>
            <pub-id pub-id-type="pmid">1584936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cervera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Balasch</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Autoimmunity and recurrent pregnancy losses.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>148</fpage>
            <page-range>148-52</page-range>
            <pub-id pub-id-type="pmid">19842070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Idowu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Merrion</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wemmer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mash</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Pettersen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kijacic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lathi</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy outcomes following 24-chromosome preimplantation genetic diagnosis in couples with balanced reciprocal or Robertsonian translocations.</article-title>
            <source>Fertil Steril</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>103</volume>
            <issue>4</issue>
            <fpage>1037</fpage>
            <page-range>1037-42</page-range>
            <pub-id pub-id-type="pmid">25712573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Negro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Formoso</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mangieri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pezzarossa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dazzi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>91</volume>
            <issue>7</issue>
            <fpage>2587</fpage>
            <page-range>2587-91</page-range>
            <pub-id pub-id-type="pmid">16621910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Otani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Roche</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mizuike</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Colls</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Escudero</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Munn&#x000e9;</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Preimplantation genetic diagnosis significantly improves the pregnancy outcome of translocation carriers with a history of recurrent miscarriage and unsuccessful pregnancies.</article-title>
            <source>Reprod Biomed Online</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>869</fpage>
            <page-range>869-74</page-range>
            <pub-id pub-id-type="pmid">17169213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franssen</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Korevaar</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>van der Veen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leschot</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Bossuyt</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Goddijn</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Reproductive outcome after chromosome analysis in couples with two or more miscarriages: index [corrected]-control study.</article-title>
            <source>BMJ</source>
            <year>2006</year>
            <month>Apr</month>
            <day>01</day>
            <volume>332</volume>
            <issue>7544</issue>
            <fpage>759</fpage>
            <page-range>759-63</page-range>
            <pub-id pub-id-type="pmid">16495333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heinonen</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Saarikoski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pystynen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Reproductive performance of women with uterine anomalies. An evaluation of 182 cases.</article-title>
            <source>Acta Obstet Gynecol Scand</source>
            <year>1982</year>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-62</page-range>
            <pub-id pub-id-type="pmid">7113692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toth</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vomstein</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Togawa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>B&#x000f6;ttcher</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hudalla</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Strowitzki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kuon</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>The impact of previous live births on peripheral and uterine natural killer cells in patients with recurrent miscarriage.</article-title>
            <source>Reprod Biol Endocrinol</source>
            <year>2019</year>
            <month>Aug</month>
            <day>31</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <pub-id pub-id-type="pmid">31472670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dakhly</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Bayoumi</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Sharkawy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gad Allah</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gouda</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Hashem</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Hatem</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>El-Khayat</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Intralipid supplementation in women with recurrent spontaneous abortion and elevated levels of natural killer cells.</article-title>
            <source>Int J Gynaecol Obstet</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>135</volume>
            <issue>3</issue>
            <fpage>324</fpage>
            <page-range>324-327</page-range>
            <pub-id pub-id-type="pmid">27614789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rasmark Roepke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hellgren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hjertberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Blomqvist</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Matthiesen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Henic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lalitkumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Strandell</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment efficacy for idiopathic recurrent pregnancy loss - a systematic review and meta-analyses.</article-title>
            <source>Acta Obstet Gynecol Scand</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>97</volume>
            <issue>8</issue>
            <fpage>921</fpage>
            <page-range>921-941</page-range>
            <pub-id pub-id-type="pmid">29603135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coomarasamy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Truchanowicz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Seed</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Small</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Quenby</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dawood</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Koot</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Bender Atik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bloemenkamp</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Briley</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Cavallaro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cheong</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Eapen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ewies</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaaijk</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Koks</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>MacLean</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mol</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sharpe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vaithilingam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Farquharson</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Kilby</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Khalaf</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Goddijn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Regan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A Randomized Trial of Progesterone in Women with Recurrent Miscarriages.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Nov</month>
            <day>26</day>
            <volume>373</volume>
            <issue>22</issue>
            <fpage>2141</fpage>
            <page-range>2141-8</page-range>
            <pub-id pub-id-type="pmid">26605928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27625.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ismail</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Peri-conceptional progesterone treatment in women with unexplained recurrent miscarriage: a randomized double-blind placebo-controlled trial.</article-title>
            <source>J Matern Fetal Neonatal Med</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>388</fpage>
            <page-range>388-394</page-range>
            <pub-id pub-id-type="pmid">28114846</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
